CAR T细胞在血液中的扩增和持久性对多发性骨髓瘤治疗效果和不良事件的影响
Influence of CAR T-cell expansion and persistence in the peripheral blood on CAR T-cell therapy efficacy and adverse events in multiple myeloma
研究分析了40名接受CAR T细胞治疗的多发性骨髓瘤患者,发现CAR T细胞在血液中的扩增和持久性与治疗效果和不良事件相关。Cilta-cel组患者CAR T细胞在血液中的扩增和持久性优于Ide-cel组,但两组总体生存率无显著差异。
To the Editor,
CAR T-cell expansion and persistence may be critical for treatment outcome and adverse events, such as neurotoxicity, cytokine release syndrome (CRS) and hematologic toxicity. Prior data suggest that high tumor burden, a history of grade ≥2 CRS, previous immune effector cell-associated neurotoxicity syndrome (ICANS), and pronounced CAR T-cell expansion may be associated with increased delayed neurotoxicity (DNT) risk [1], including cranial nerve palsies (CNP) and neurocognitive movement disorders (MNT), which can be severe and difficult to manage [2]. Here we analyzed the clinical outcome and the influence of BCMA-CAR T-cell expansion in peripheral blood (PB) by flow cytometry in our first 40 CAR T-treated multiple myeloma (MM) patients (cilta-cel n = 28, ide-cel n = 12) (Supplementary Table S1). For methods see Supplementary Material.
As previously described, cilta-cel demonstrated a better overall response than ide-cel with a significant difference in progression-free-survival [3]. There was no difference in overall survival in our cohort (Supplementary Fig. S1). Since the efficacy of ide-cel and cilta-cel is different and the ide-cel cohort is too small, we performed additional subgroup analyses only in the larger cilta-cel cohort. Here, we also assessed the impact of bone marrow (BM) infiltration, CAR-HEMATOTOX (HT)-Score, CAR T-cell expansion, high-risk (HR) cytogenetics and extramedullary disease (EMD) on survival. The results are summarized in Supplementary Table S2 and Supplementary Fig. S2. While BM infiltration ≥50% was significantly associated with lower progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p = 0.02) as compared to a lower BM infiltration p(Supplementary Fig. S2A, B), there was no statistically significant difference in PFS and OS in the other subgroups including CAR T-cell expansion (Supplementary Fig. S2C–J).
Evaluable patients were categorized as poor (n = 20) and strong expanders (n = 19) based on therapy-specific thresholds. CAR T-cell expansion, measured via flow cytometry in PB, was classified based on product-specific cut-offs defined by the median of the highest measured CAR T-cell level of each individual patient with poor expansion <58/μL for cilta-cel or <19/μL for ide-cel, and strong expansion ≥58/μL and ≥19/μL, respectively. One patient was excluded from the expansion analysis due to limited CAR T-cell quantification data during the early phase of the study. While early technical constraints affected other cases, those patients had sufficient data points to allow determination of expansion kinetics (Fig. 1). The analyses of poor and strong expanders are summarized in Supplementary Table S3. Baseline characteristics were generally balanced. Prior treatment exposure was comparable (median of 4 prior treatment lines, no significant differences regarding prior autologous or allogeneic stem cell transplantation (SCT), application of bispecific antibodies or polychemotherapy). One patient (1/19 [5%]) in the strong expansion group had received ide-cel prior to the cilta-cel therapy [4]. The groups were also comparable in terms of BM infiltration, cytogenetic risk, ISS stage, and EMD frequencies.
CAR T-cell expansion in PB following treatment with a cilta-cel and ide-cel and according to response: b ≥VGPR, c ≤PR. PB Peripheral blood, BCMA B-cell maturation antigen, cilta-cel Ciltacabtagene autoleucel, ide-cel Idecabtagene vicleucel, PD Progressive Disease, SD Stable Disease, MR Minimal Response, PR Partial Response, vgPR Very Good Partial Response, nCR Near Complete Response, CR Complete Response.
Although data on ide-cel are very limited, BCMA CAR T-cell peak expansion in PB seem to occur earlier in patients treated with ide-cel compared to cilta-cel, while persistence of CAR-T-cells in PB was superior for cilta-cel vs ide-cel with detectable CAR T-cells for a median of 70 (0–308) and 40 (0–204) days, respectively (Fig. 1a). Patients receiving cilta-cel or ide-cel who achieved ≥VGPR showed higher CAR T-cell expansion and longer persistence, with median peak levels of 272 cells/µL (range, 5–17,780 cells/µL) ≤day 15 post-infusion (Fig. 1b). Among poor responders CAR T-cell levels were consistently lower over time (Fig. 1c). None of the poor responders had detectable CAR T cells beyond day 200. Two poor responders had no detectable CAR T-cell expansion at any measured time point after infusion. One received cilta-cel for progressive, penta-drug-refractory disease, while the other received ide-cel as eighth-line therapy in progressive disease. Both received bridging therapy, achieved only stable disease or minimal response, subsequently progressed, and died during follow-up.
Lymphopenia prior to treatment initiation was associated with poor CAR T-cell expansion. At the pre-apheresis timepoint, poor expanders were more likely to exhibit severe lymphopenia (<500/μL) compared to strong expanders (40% vs 16%, p = 0.16), although not reaching statistical significance. This trend remained numerically evident at the pre-infusion assessment (50% vs 26%, p = 0.23). Inflammatory markers showed no significant differences: elevated CRP (>5 mg/L) occurred in 45% vs 53% (p = 0.75), hyperferritinemia (>500 μg/L) in 75% vs 53% (p = 0.19). A HT score ≥2 was observed in 55% vs 68% (p = 0.51).
Adverse events are summarized in Supplementary Table S4 and hematotoxicity in Supplementary Table S5. CRS and ICANS were the most common non-hematological treatment-emergent adverse events. In the entire cohort, CRS occurred in 82.5% of which 25/28 (89.3%) were observed in the cilta-cel cohort and 8/12 (66.7%) in the ide-cel cohort, all grade 1 or 2. ICANS was observed in 4 patients, all in the cilta-cel group (10% of the total cohort, 14.3% of the cilta-cel cohort), with grade 1 and 2 in two patients each. One patient treated with cilta-cel developed DNT (1/28, 3.6%) with isolated facial nerve palsy 22 days after CAR T-cell infusion which resolved under corticosteroid therapy. Two cases of secondary malignancies were observed, one t-AML and one cutaneous squamous cell carcinoma. The proportion of patients with significant leukopenia, neutropenia, or thrombocytopenia was comparable in cilta-cel and ide-cel patients.
CRS incidence was high in both groups of poor vs strong expanders (any grade: 80% vs 84%; p = 1.00; grade ≥2: 50% vs 53%; p = 1.00), with comparable tocilizumab use (65% vs 79%; p = 0.48). Notably, neurotoxicity was exclusively observed in strong expanders (26% vs 0%; p = 0.02), including 4 cases (21%) meeting ICANS criteria (any grade; p = 0.05). Patients with grade 1 ICANS had peak CAR T-cell counts of 1231/µL and 17,780/µL, while patients with grade 2 ICANS had peak counts of 5282/µL and 59/µL. The patient who developed a DNT with unilateral facial nerve palsy received cilta-cel in partial response after five prior lines of therapy. Facial nerve palsy occurred on day +22 with CAR T-cell expansion of 164 cells/µL and resolved following steroids.
Interestingly, we observed a positive association between pre-apheresis lymphocyte count and CAR T expansion, supporting the hypothesis that lymphocyte count at leukapheresis – likely modifiable through previous therapy – may be one factor for treatment success [5, 6]. In this context, future research should explore whether pre-apheresis lymphocyte optimization through individualized holding therapies may enhance CAR T expansion and efficacy. In addition, bridging therapy for example with a change to bispecifics can lead to a very sufficient reduction of tumor load which may influence CAR T cell expansion after infusion and should be further explored in future studies.
While prior studies have demonstrated reduced expansion post-autologous SCT [5], we did not observe significant association between expansion and prior autologous SCT or the number of therapy lines before CAR T-cells. Although strong expanders tended to have higher frequencies of adverse baseline features (e.g., EMD, HR cytogenetics, ISS ≥ II, and high BM infiltration), none reached statistical significance. Like our findings, a recent study found no statistically significant association between CAR T-cell expansion and biochemical markers such as CRP and ferritin. The study also evaluated the impact of systemic steroids and CAR T-cell dose, but neither significantly affected expansion [7].
We observed a significant association between strong CAR T expansion and neurotoxicity, including mostly ICANS, supporting a link between expansion kinetics and neurotoxicity [8,9,10,11,12], but no association between strong expansion and occurrence of CRS, as previously described [6]. The lower ICANS rate observed in CARTITUDE-4 has been attributed to earlier use of CAR-T cells contributing to a more favorable safety profile [13]. The rate of DNT observed in our cilta-cel cohort (3.6%) was comparable to that reported in other studies [1, 2, 14,15,16]. No DNT was observed in the ide-cel group. These findings align with a previous study suggesting an early peak expansion with ide-cel but a stronger, prolonged expansion with cilta-cel - associated with increased neurotoxicity [3].
This study has several limitations. The relatively small sample size limits statistical power and increases the influence of individual cases. The heterogeneous patient population with different pretreatments and baseline characteristics reduces comparability. In addition, varying follow-up times make the assessment of endpoints such as PFS and OS less consistent across patients. Finally, the retrospective design may introduce bias and limits the generalizability of the findings. Nevertheless, our preliminary findings indicate that CAR T-cell expansion is associated with treatment response in MM. Greater CAR T-cell expansion, particularly following cilta-cel infusion, was associated with deeper responses, whereas no significant association with PFS or OS was observed, but may also increase the risk of ICANS. The relevance of our findings remains to be determined in additional larger studies.
References
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24.
Cohen AD, Parekh S, Santomasso BD, Gállego Pérez-Larraya J, Van De Donk NWCJ, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32.
Merz M, Albici A, von Tresckow B, Rathje K, Fenk R, Holderried T, et al. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study. HemaSphere. 2025;9:e70070.
Mobascher P, Engelhardt M, Wäsch R. Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma. Ann Hematol. 2025;104:2055–8.
Jin C, Chen R, Fu S, Zhang M, Teng Y, Yang T, et al. Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma. J Immunother Cancer. 2025;13:e010687.
Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma. Leukemia. 2024;38:372–82.
Atanackovic D, Luetkens T, Schneider D, Hu P, Wang X, Shetty AC, et al. Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. Nat Commun. 2025;16:6154.
Graham CE, Lee WH, Wiggin HR, Supper VM, Leick MB, Birocchi F, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity. Blood. 2023;142:1248–52.
Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141:219–30.
Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism following BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:2099–103.
Hosoya H, Velayati A, Dima D, Jensen A, Portuguese AJ, Hovanky V, et al. Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma. Blood 2026;148:1961-1972.
Engelhardt M, Wäsch R. Neurotoxicity with CAR T cells in myeloma deciphered? Blood 2026;148:1947-1948.
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389:335–47.
Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025;145:85–97.
Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41:1265–74.
Van De Donk NWCJ, Sidana S, Schecter JM, Jackson CC, Lendvai N, De Braganca KC, et al. Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel). Blood. 2023;142:3501.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
University Medical Center Freiburg, Hematology and Oncology Department, Faculty of Freiburg, Freiburg im Breisgau, Germany
M. Boettger, P. Sauerborn, M. Sieder, C. Greil, M. Engelhardt & R. Wäsch
Clinical Trials Unit, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany
G. Ihorst
Institute of Physics, University of Freiburg, Freiburg im Breisgau, Germany
S. Ochoa
Authors
- M. Boettger
- P. Sauerborn
- G. Ihorst
- S. Ochoa
- M. Sieder
- C. Greil
- M. Engelhardt
- R. Wäsch
Contributions
RW and ME designed the study. MB acquired the data. MB, RW and ME analyzed the data and wrote the paper. GI performed the statistical analysis. MS performed flow cytometry. PS, SO, CG critically discussed and interpreted data.
Corresponding author
Correspondence to R. Wäsch.
Ethics declarations
Competing interests
MB, PS, GI, SO, MS, and CG declare no competing interests. ME consulted for and/or received honoraria from Amgen, BMS, GSK, Johnson & Johnson, Pfizer, Sanofi, Stemline, Takeda and received research funding from BMS, Johnson & Johnson and Pfizer all paid to UKF. RW consulted for and/or received honoraria from Abbvie, Alexion, Amgen, BMS, Johnson & Johnson, Kite/Gilead, Novartis, Pfizer, Sanofi, Takeda and received research funding from Johnson & Johnson and Sanofi all paid to UKF.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Boettger, M., Sauerborn, P., Ihorst, G. et al. Influence of CAR T-cell expansion and persistence in the peripheral blood on CAR T-cell therapy efficacy and adverse events in multiple myeloma. Bone Marrow Transplant (2026). https://doi.org/10.1038/s41409-026-03083-w
Received: 27 June 2026
Revised: 01 October 2026
Accepted: 16 October 2026
Published: 07 November 2026
Version of record: 07 November 2026
DOI: https://doi.org/10.1038/s41409-026-03083-w
来源:Nature 健康护理主题 · nature.com